1378911-93-3

Upstream product

• 1378911-49-9 C₃₆H₃₀O₉ 
• 10310-21-1 2-Amino-6-chloropurin 
• 666723-03-1 1,2,3,5-tetra-O-benzoyl-2-C-allyl-D-ribofuranose 

Downstream Products

• 1378911-99-9 C₃₃H₅₁N₅O₈Si₂ 
• 1378911-97-7 C₃₃H₄₉N₅O₇Si₂ 
• 1378912-00-5 C₂₁H₂₃N₅O₆ 
• 1378912-03-8 C₃₂H₄₉N₅O₈Si₂ 
• 1378911-19-3 C₃₃H₅₁N₅O₁₀SSi₂ 
• 1378911-20-6 C₃₂H₄₇N₅O₇Si₂ 
• 1378912-04-9 C₂₀H₂₁N₅O₆ 
• 1378912-65-2 (2S)-methyl 2-(((((4R,5R,7R,8R)-5-(2-amino-6-methoxy-9H-purin-9-yl)-8-hydroxy-1,6-dioxaspiro[3.4]octan-7-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate 
• 1378912-75-4 C₂₇H₃₇N₆O₉P 

Relevant academic research and scientific papers

Use of 2′-spirocyclic ethers in HCV nucleoside design

Conformationally restricted 2′-spironucleosides and their prodrugs were synthesized as potential anti-HCV agents. Although the replicon activity of the new agents containing pyrimidine bases was modest, the triphosphate of a 2′-oxetane cytidine analogue demonstrated potent intrinsic biochemical activity against the NS5B polymerase, with IC50 = 8.48 μM. Activity against NS5B bearing the S282T mutation was reduced. Phosphoramidate prodrugs of a 2′-oxetane 2-amino-6-O-methyl-purine nucleoside demonstrated potent anti-HCV activity in vitro, and the corresponding triphosphate retained similar potent activity against both wild-type and S282T HCV NS5B polymerase.